162 related articles for article (PubMed ID: 25612680)
1. Discovery of Novel N-alkyl 4-anilinofuro[2,3-b]quinoline Derivatives (CIL-102 Derivatives) Against Castration-resistant Human Prostate Cancers.
Lo WF; Chou YW; Tseng CH; Shiu YH; Chen YW; Yang SC; Chen YL; Lin MF; Tzeng CC
Anticancer Agents Med Chem; 2015; 15(4):493-500. PubMed ID: 25612680
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and antiproliferative evaluation of 4-anilino-n-methoxyfuro[2,3-b]quinoline derivatives (n=6, 7). Part 5.
Chen YL; Lin HC; Yang CN; Lu PJ; Tzeng CC
Chem Biodivers; 2008 Feb; 5(2):267-78. PubMed ID: 18293440
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 4-anilinofuro[2,3-b]quinoline derivatives as selective and orally active compounds against non-small-cell lung cancers.
Chen YW; Chen YL; Tseng CH; Liang CC; Yang CN; Yao YC; Lu PJ; Tzeng CC
J Med Chem; 2011 Jul; 54(13):4446-61. PubMed ID: 21599000
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and anticancer evaluation of certain 4-anilinofuro[2,3-b]quinoline and 4-anilinofuro[3,2-c]quinoline derivatives.
Chen YL; Chen IL; Wang TC; Han CH; Tzeng CC
Eur J Med Chem; 2005 Sep; 40(9):928-34. PubMed ID: 15913847
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and cytotoxic evaluation of novel furo[2,3-b]quinoline derivatives.
Wang B; Li Q; Shi W; Chen L; Sun J
Chem Biol Drug Des; 2018 Apr; 91(4):957-961. PubMed ID: 29197162
[TBL] [Abstract][Full Text] [Related]
6. Development of Furo[2,3-b]quinoline Derivatives with Anti-Breast Cancer Property by Targeting Topoisomerase II.
Wang Y; Li N; Jiang N; Chen L; Sun J
Anticancer Agents Med Chem; 2021; 21(12):1482-1489. PubMed ID: 33155915
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of 4-anilinoquinoline derivatives as novel potent tubulin depolymerization agents.
Zhou Y; Yan W; Cao D; Shao M; Li D; Wang F; Yang Z; Chen Y; He L; Wang T; Shen M; Chen L
Eur J Med Chem; 2017 Sep; 138():1114-1125. PubMed ID: 28763646
[TBL] [Abstract][Full Text] [Related]
8. Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer.
Miller DR; Tzeng CC; Farmer T; Keller ET; Caplan S; Chen YS; Chen YL; Lin MF
Cancer Lett; 2018 Nov; 436():96-108. PubMed ID: 30077739
[TBL] [Abstract][Full Text] [Related]
9. 4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors.
Zhang N; Wu B; Boschelli DH; Golas JM; Boschelli F
Bioorg Med Chem Lett; 2009 Sep; 19(17):5071-4. PubMed ID: 19632113
[TBL] [Abstract][Full Text] [Related]
10. 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. Part 2. The impact of bridging groups at position C-2.
Lee HY; Chang JY; Nien CY; Kuo CC; Shih KH; Wu CH; Chang CY; Lai WY; Liou JP
J Med Chem; 2011 Dec; 54(24):8517-25. PubMed ID: 22060033
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and cytotoxic evaluation of certain 4-(phenylamino)furo[2,3-b]quinoline and 2-(furan-2-yl)-4-(phenylamino)quinoline derivatives.
Zhao YL; Chen YL; Tzeng CC; Chen IL; Wang TC; Han CH
Chem Biodivers; 2005 Feb; 2(2):205-14. PubMed ID: 17191973
[TBL] [Abstract][Full Text] [Related]
12. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors.
Shi L; Wu TT; Wang Z; Xue JY; Xu YG
Eur J Med Chem; 2014 Sep; 84():698-707. PubMed ID: 25064347
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and antitumor evaluation of quinoline-imidazole derivatives.
Xiao Z; Lei F; Chen X; Wang X; Cao L; Ye K; Zhu W; Xu S
Arch Pharm (Weinheim); 2018 Jun; 351(6):e1700407. PubMed ID: 29732607
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and in vitro antiproliferative activity of new 11-aminoalkylamino-substituted 5H- and 6H-indolo[2,3-b]quinolines; structure-activity relationships of neocryptolepines and 6-methyl congeners.
Wang L; Switalska M; Mei ZW; Lu WJ; Takahara Y; Feng XW; El-Sayed Iel-T; Wietrzyk J; Inokuchi T
Bioorg Med Chem; 2012 Aug; 20(15):4820-9. PubMed ID: 22748378
[TBL] [Abstract][Full Text] [Related]
15. 2-Anilino-3-Aroylquinolines as Potent Tubulin Polymerization Inhibitors.
Srikanth PS; Nayak VL; Suresh Babu K; Kumar GB; Ravikumar A; Kamal A
ChemMedChem; 2016 Sep; 11(18):2050-62. PubMed ID: 27465681
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and antiproliferative evaluation of 6-aryl-11-iminoindeno[1,2-c]quinoline derivatives.
Tseng CH; Tzeng CC; Chung KY; Kao CL; Hsu CY; Cheng CM; Huang KS; Chen YL
Bioorg Med Chem; 2011 Dec; 19(24):7653-63. PubMed ID: 22079254
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and antiproliferative evaluation of certain indolo[3,2-c]quinoline derivatives.
Lu CM; Chen YL; Chen HL; Chen CA; Lu PJ; Yang CN; Tzeng CC
Bioorg Med Chem; 2010 Mar; 18(5):1948-57. PubMed ID: 20171108
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of novel 5-(3-alkylquinolin-2-yl)-3-aryl isoxazole derivatives and their cytotoxic activity.
Sambasiva Rao P; Kurumurthy C; Veeraswamy B; Poornachandra Y; Ganesh Kumar C; Narsaiah B
Bioorg Med Chem Lett; 2014 Mar; 24(5):1349-51. PubMed ID: 24507927
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Zou M; Li J; Jin B; Wang M; Chen H; Zhang Z; Zhang C; Zhao Z; Zheng L
Bioorg Chem; 2021 Sep; 114():105200. PubMed ID: 34375195
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of 3-(4-fluorophenyl)-1H-pyrazole derivatives as androgen receptor antagonists.
Guo G; Liu J; Wang G; Zhang D; Lu J; Zhao G
Anticancer Drugs; 2016 Apr; 27(4):278-85. PubMed ID: 26633887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
